Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Antibe Therapeutics Inc (ATE.TO)

Antibe Therapeutics Inc (ATE.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 15,638
  • Shares Outstanding, K 53,009
  • Annual Sales, $ 0 K
  • Annual Income, $ -19,475 K
  • 60-Month Beta -0.19
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.60
Trade ATE.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.35
  • Most Recent Earnings $-0.08 on N/A
  • Latest Earnings Date 02/13/24
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.14
  • Number of Estimates 1
  • High Estimate -0.14
  • Low Estimate -0.14
  • Prior Year -0.06
  • Growth Rate Est. (year over year) -133.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1500 +96.67%
on 04/01/24
0.4900 -39.80%
on 03/14/24
-0.1550 (-34.44%)
since 03/08/24
3-Month
0.1500 +96.67%
on 04/01/24
1.1400 -74.12%
on 01/09/24
-0.7950 (-72.94%)
since 01/08/24
52-Week
0.1500 +96.67%
on 04/01/24
1.2300 -76.02%
on 11/09/23
-0.2650 (-47.32%)
since 04/06/23

Most Recent Stories

More News
Stocks in play: Antibe Therapeutics Inc.

Is extending the Early Warrant Exercise Incentive Program for its 6.4 million outstanding and unlisted ...

ATE.TO : 0.2950 (+13.46%)
Stocks in play: Antibe Therapeutics Inc.

Announces that it is extending the expiry date and amending the exercise price of the common share purchase ...

ATE.TO : 0.2950 (+13.46%)
Stocks in play: Antibe Therapeutics Inc.

Announced the completion of the pharmacokinetic/pharmacodynamic study of otenaproxesul’s faster-absorbing ...

ATE.TO : 0.2950 (+13.46%)
Stocks in play: Antibe Therapeutics Inc

Announced the initiation of the pharmacokinetic/pharmacodynamic study of otenaproxesul’s faster-absorbing ...

ATE.TO : 0.2950 (+13.46%)
Stocks in play: Antibe Therapeutics Inc.

Announced Health Canada’s approval to initiate the pharmacokinetic/pharmacodynamic study of otenaproxesul’s ...

ATE.TO : 0.2950 (+13.46%)
Toronto Stock Exchange, Antibe Therapeutics Inc., View From The C-Suite

/PRNewswire/ - Dan Legault, Chief Executive Officer and Director, Antibe Therapeutics Inc. (TSX: ATE) shares his Company's story in an interview with TMX Group....

ATE.TO : 0.2950 (+13.46%)
Toronto Stock Exchange, Antibe Therapeutics Inc., View From The C-Suite

/CNW/ - Dan Legault, Chief Executive Officer and Director, Antibe Therapeutics Inc. (TSX: ATE) shares his Company's story in an interview with TMX Group. The...

ATE.TO : 0.2950 (+13.46%)
Antibe’s Chief Medical Officer to Present at the 2023 Precision in Clinical Trials Summit

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, today announced its...

ATE.TO : 0.2950 (+13.46%)
ATBPF : 0.2156 (+13.47%)
Antibe to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, today announced its...

ATE.TO : 0.2950 (+13.46%)
ATBPF : 0.2156 (+13.47%)
Stocks in play: Antibe Therapeutics Inc.

Provided a corporate update. Further to Antibe’s update of February 15, 2023, the Company has now selected ...

ATE.TO : 0.2950 (+13.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated...

See More

Key Turning Points

3rd Resistance Point 0.4333
2nd Resistance Point 0.3917
1st Resistance Point 0.3433
Last Price 0.2950
1st Support Level 0.2533
2nd Support Level 0.2117
3rd Support Level 0.1633

See More

52-Week High 1.2300
Fibonacci 61.8% 0.8174
Fibonacci 50% 0.6900
Fibonacci 38.2% 0.5626
Last Price 0.2950
52-Week Low 0.1500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar